AlloVir
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch AlloVir and buy or sell other stocks, ETFs, and their options commission-free!About ALVR
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases.
CEOAndrew Oxtoby, MBA
CEOAndrew Oxtoby, MBA
Employees6
Employees6
HeadquartersBerkeley Heights, New Jersey
HeadquartersBerkeley Heights, New Jersey
Founded
Founded
Employees6
Employees6
ALVR Key Statistics
Market cap183.47M
Market cap183.47M
Price-Earnings ratio-1.30
Price-Earnings ratio-1.30
Dividend yield—
Dividend yield—
Average volume237.67K
Average volume237.67K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$12.90
52 Week high$12.90
52 Week low$2.14
52 Week low$2.14
Stock Snapshot
With a market cap of 183.47M, AlloVir(ALVR) trades at $9.81. The stock has a price-to-earnings ratio of -1.30.
On 2025-12-26, AlloVir(ALVR) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for AlloVir(ALVR) stock has reached 0, versus its average volume of 237.67K.
The stock's 52-week range extends from a low of $2.14 to a high of $12.90.
The stock's 52-week range extends from a low of $2.14 to a high of $12.90.
People also own
Based on the portfolios of people who own ALVR. This list is generated using Robinhood data, and it’s not a recommendation.